Nature	nature	O	O	O	O
,	,	O	O	O	O
time	time	O	O	O	O
course	course	O	O	O	O
and	and	O	O	O	O
dose	dose	O	O	O	O
dependence	dependence	O	O	O	O
of	of	O	O	O	O
zidovudine-related	zidovudine-related	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
:	:	O	O	O	O
results	results	O	O	O	O
from	from	O	O	O	O
the	the	O	O	O	O
Multicenter	multicenter	O	O	O	O
Canadian	canadian	O	O	O	O
Azidothymidine	azidothymidine	CHEMICALS	O	OTHERS	I
Trial	trial	O	O	O	O
.	.	O	O	O	O
To	to	O	O	O	O
characterize	characterize	O	O	O	O
the	the	O	O	O	O
nature	nature	O	O	O	O
,	,	O	O	O	O
time	time	O	O	O	O
course	course	O	O	O	O
and	and	O	O	O	O
dose	dose	O	O	O	O
dependency	dependency	O	O	O	O
of	of	O	O	O	O
zidovudine-related	zidovudine-related	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
,	,	O	O	O	O
we	we	O	O	O	O
undertook	undertook	O	O	O	O
a	a	O	O	O	O
multicenter	multicenter	O	O	O	O
,	,	O	O	O	O
prospective	prospective	O	O	O	O
,	,	O	O	O	O
dose-range	dose-range	O	O	O	O
finding	finding	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

Our	our	O	O	O	O
study	study	O	O	O	O
group	group	O	O	O	O
consisted	consisted	O	O	O	O
of	of	O	O	O	O
74	74	O	O	O	O
HIV-positive	hiv-positive	O	O	O	O
homosexual	homosexual	O	O	O	O
men	men	O	O	O	O
belonging	belonging	O	O	O	O
to	to	O	O	O	O
groups	groups	O	O	O	O
II	ii	O	O	O	O
B	b	O	O	O	O
,	,	O	O	O	O
III	iii	O	O	O	O
and	and	O	O	O	O
IV	iv	O	O	O	O
C2	c2	O	O	O	O
from	from	O	O	O	O
the	the	O	O	O	O
Centers	centers	O	O	O	O
for	for	O	O	O	O
Disease	disease	O	O	O	O
Control	control	O	O	O	O
(	(	O	O	O	O
CDC	cdc	O	O	O	O
)	)	O	O	O	O
classification	classification	O	O	O	O
of	of	O	O	O	O
HIV	hiv	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
.	.	O	O	O	O

Following	following	O	O	O	O
a	a	O	O	O	O
3-week	3-week	O	O	O	O
observation	observation	O	O	O	O
period	period	O	O	O	O
,	,	O	O	O	O
volunteers	volunteers	O	O	O	O
were	were	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
zidovudine	zidovudine	CHEMICALS	O	OTHERS	I
600	600	O	O	O	O
mg/day	mg/day	O	O	O	O
for	for	O	O	O	O
18	18	O	O	O	O
weeks	weeks	O	O	O	O
,	,	O	O	O	O
900	900	O	O	O	O
mg/day	mg/day	O	O	O	O
for	for	O	O	O	O
9	9	O	O	O	O
weeks	weeks	O	O	O	O
and	and	O	O	O	O
1200	1200	O	O	O	O
mg/day	mg/day	O	O	O	O
for	for	O	O	O	O
9	9	O	O	O	O
weeks	weeks	O	O	O	O
,	,	O	O	O	O
followed	followed	O	O	O	O
by	by	O	O	O	O
a	a	O	O	O	O
washout	washout	O	O	O	O
period	period	O	O	O	O
of	of	O	O	O	O
6	6	O	O	O	O
weeks	weeks	O	O	O	O
after	after	O	O	O	O
which	which	O	O	O	O
they	they	O	O	O	O
were	were	O	O	O	O
re-started	re-started	O	O	O	O
on	on	O	O	O	O
1200	1200	O	O	O	O
mg/day	mg/day	O	O	O	O
or	or	O	O	O	O
the	the	O	O	O	O
highest	highest	O	O	O	O
tolerated	tolerated	O	O	O	O
dose	dose	O	O	O	O
at	at	O	O	O	O
8-hourly	8-hourly	O	O	O	O
intervals	intervals	O	O	O	O
.	.	O	O	O	O

Subjects	subjects	O	O	O	O
were	were	O	O	O	O
randomly	randomly	O	O	O	O
assigned	assigned	O	O	O	O
to	to	O	O	O	O
4-hourly	4-hourly	O	O	O	O
or	or	O	O	O	O
8-hourly	8-hourly	O	O	O	O
regimens	regimens	O	O	O	O
within	within	O	O	O	O
CDC	cdc	O	O	O	O
groups	groups	O	O	O	O
while	while	O	O	O	O
taking	taking	O	O	O	O
600	600	O	O	O	O
and	and	O	O	O	O
1200	1200	O	O	O	O
mg/day	mg/day	O	O	O	O
.	.	O	O	O	O

Clinical	clinical	O	O	O	O
and	and	O	O	O	O
laboratory	laboratory	O	O	O	O
evaluations	evaluations	O	O	O	O
were	were	O	O	O	O
performed	performed	O	O	O	O
at	at	O	O	O	O
3-week	3-week	O	O	O	O
intervals	intervals	O	O	O	O
.	.	O	O	O	O

Symptomatic	symptomatic	O	O	O	O
adverse	adverse	O	O	O	O
effects	effects	O	O	O	O
were	were	O	O	O	O
present	present	O	O	O	O
in	in	O	O	O	O
96	96	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
subjects	subjects	O	O	O	O
,	,	O	O	O	O
most	most	O	O	O	O
commonly	commonly	O	O	O	O
nausea	nausea	O	DISEASE	OTHERS	I
(	(	O	O	O	O
64	64	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
fatigue	fatigue	O	DISEASE	OTHERS	I
(	(	O	O	O	O
55	55	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
headache	headache	O	DISEASE	OTHERS	I
(	(	O	O	O	O
49	49	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
were	were	O	O	O	O
generally	generally	O	O	O	O
self-limited	self-limited	O	O	O	O
,	,	O	O	O	O
reappearing	reappearing	O	O	O	O
briefly	briefly	O	O	O	O
at	at	O	O	O	O
each	each	O	O	O	O
dose	dose	O	O	O	O
increment	increment	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
decrease	decrease	O	O	O	O
in	in	O	O	O	O
hemoglobin	hemoglobin	O	O	O	O
occurred	occurred	O	O	O	O
shortly	shortly	O	O	O	O
after	after	O	O	O	O
initiation	initiation	O	O	O	O
of	of	O	O	O	O
therapy	therapy	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
was	was	O	O	O	O
not	not	O	O	O	O
dose	dose	O	O	O	O
dependent	dependent	O	O	O	O
and	and	O	O	O	O
reversed	reversed	O	O	O	O
rapidly	rapidly	O	O	O	O
upon	upon	O	O	O	O
discontinuation	discontinuation	O	O	O	O
of	of	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
red	red	O	O	O	O
blood	blood	O	O	O	O
cell	cell	O	O	O	O
count	count	O	O	O	O
decrease	decrease	O	O	O	O
,	,	O	O	O	O
a	a	O	O	O	O
mean	mean	O	O	O	O
cell	cell	O	O	O	O
volume	volume	O	O	O	O
increase	increase	O	O	O	O
and	and	O	O	O	O
a	a	O	O	O	O
granulocyte	granulocyte	O	O	O	O
count	count	O	O	O	O
decrease	decrease	O	O	O	O
developed	developed	O	O	O	O
early	early	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
dose-independent	dose-independent	O	O	O	O
fashion	fashion	O	O	O	O
,	,	O	O	O	O
reverting	reverting	O	O	O	O
at	at	O	O	O	O
least	least	O	O	O	O
partially	partially	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
washout	washout	O	O	O	O
phase	phase	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
decrease	decrease	O	O	O	O
in	in	O	O	O	O
reticulocyte	reticulocyte	O	O	O	O
count	count	O	O	O	O
was	was	O	O	O	O
dose	dose	O	O	O	O
related	related	O	O	O	O
between	between	O	O	O	O
600	600	O	O	O	O
and	and	O	O	O	O
900	900	O	O	O	O
mg/day	mg/day	O	O	O	O
with	with	O	O	O	O
no	no	O	O	O	O
further	further	O	O	O	O
change	change	O	O	O	O
when	when	O	O	O	O
the	the	O	O	O	O
dose	dose	O	O	O	O
was	was	O	O	O	O
escalated	escalated	O	O	O	O
to	to	O	O	O	O
1200	1200	O	O	O	O
mg/day	mg/day	O	O	O	O
.	.	O	O	O	O

Bone	bone	O	O	O	O
marrow	marrow	O	O	O	O
changes	changes	O	O	O	O
occurred	occurred	O	O	O	O
rapidly	rapidly	O	O	O	O
as	as	O	O	O	O
demonstrated	demonstrated	O	O	O	O
by	by	O	O	O	O
megaloblastosis	megaloblastosis	O	O	OTHERS	I
in	in	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
65	65	O	O	O	O
specimens	specimens	O	O	O	O
at	at	O	O	O	O
week	week	O	O	O	O
18.(ABSTRACT	18.(abstract	O	O	O	O
TRUNCATED	truncated	O	O	O	O
AT	at	O	O	O	O
250	250	O	O	O	O
WORDS	words	O	O	O	O
)	)	O	O	O	O

